- Catalytic Asymmetric Dearomative 1,3-Dipolar Cycloaddition of 2-Nitrobenzothiophenes and Isatin-Derived Azomethine Ylides
-
An enantioselective dearomative 1,3-dipolar cycloaddition of 2-nitrobenzothiophenes and isatin-derived azomethine ylides with a bifunctional hydrogen-bonding thiourea catalyst was established, giving polyheterocyclic compounds in excellent results (up to 99% yield, >20:1 dr for all cases and up to 99% ee). The enantioselectivity could be reversed by the bifunctional hydrogen-bonding squaramide catalyst containing the same chiral source as in the thiourea catalyst. DFT calculations revealed the origin of the observed stereochemistry and the reversal of enantioselectivity.
- Zhao, Jian-Qiang,Zhou, Shun,Yang, Lei,Du, Hong-Yan,You, Yong,Wang, Zhen-Hua,Zhou, Ming-Qiang,Yuan, Wei-Cheng
-
supporting information
p. 8600 - 8605
(2021/11/13)
-
- The phosphorescent compounds and organic light emitting diode device
-
A phosphorescent compound is disclosed. The phosphorescent compound represented by the following Chemical Formula 1, where X, Y, and Z are each selected from the group consisting of carbon and nitrogen, and when x, y, and z are all carbon, R is any one selected from the group consisting of carbazole, α-carboline, β-carboline, γ-carboline, fluorine, dibenzothiophene, dibenzofuran, triphenylsilane, tetraphenylsilane, pyridine, quinoline, isoquinoline, pyrimidine, diphenylphosphineoxide, and substituents thereof.
- -
-
-
- 5-HT1F agonists
-
The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT1freceptors and inhibiting protein extravasation in a mammal.
- -
-
-
- Azabicyclic inhibitors of serotonin reuptake
-
This invention provides 3-(bicyclic heteroaryl)-8-azabicyclo[3.2.1]oct-2-enes and 3-(bicyclic heteroaryl)-8-azabicyclo[3.2.1]octanes of furmula (I) which are useful for the inhibition of serotonin reuptake in mammals. whereA-B is -C=CH- or -CH-CH2/s
- -
-
-
- SUBSTITUTED HETEROAROMATIC 5-HT1F AGONISTS
-
This invention provides novel 5-HT 1F agonists of the Formula STR1 in which X, Y, E, R, A, B, and n are as defined in the specification, which are useful for the treatment of migraine and associated disorders.
- -
-
-
- COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS
-
A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1 A receptor. The compounds are particularly useful for alleviating the symptoms of n
- -
-
-
- COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS
-
A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1 A receptor. The compounds are particularly useful for alleviating the symptoms of n
- -
-
-
- Substituted heteroaromatic 5-HT 1F agonists
-
This invention provides novel 5-HT1Fagonists of the Formula in which X, Y, E, R, A, B, and n are as defined in the specification, which are useful for the treatment of migraine and associated disorders.
- -
-
-
- COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS
-
A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1 A receptor. The compounds are particularly useful for alleviating the symptoms of n
- -
-
-
- Compounds having effects on serotonin-related systems
-
A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor. The compounds are particularly useful for alleviating the sym
- -
-
-
- 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake
-
The pharmaceutical use of novel compounds of formula I: where Z is a structure of formula A-B is -C=CH- or -C(R5)-CH2-; X is S or NR4; R1is H, halo, formyl, C1-C4alkyl, C1-C4alkoxy, thienylmethyloxy, 4,5-dihydrothiazol-2-yl, cyano, nitro, carboxamido, trifluoromethyl or hydroxy; R2is H or halo; R3is H, C1-C4alkyl, (C1-C4alkylene)-aryl, or -CH2-Y-NR7R8; R4is H, C1-C4alkyl, C1-C5acyl, or phenylsulfonyl; R5is H or OH; R6is H or methyl; Y is -CH2- or -C(O)-; R7is pyridinyl; and R8is H or -C(O)-(C3-C6cycloalkyl); and pharmaceutically acceptable salts thereof.
- -
-
-
- COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS
-
A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1 A receptor. The compounds are particularly useful for alleviating the symptoms of n
- -
-
-